Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study - PubMed https://t.co/wSywKOILIc
【骨粗鬆症治療は生命予後を良くするか?】 骨粗鬆症がわるいのはわかったけど、治療すれば良くなるのか? 報告は少ないですが比較的数の多いデータもあります 窒素含有BPは心血管イベントのリスクを減らし予後を伸ばすようです🤔 https://t.co/DOMhON2gnR
@karlhoods This paper was quoted and suggests a reduction in mortality https://t.co/orFvX1mWh6
RT @iofsaludosea: #Osteoporosis Int: la reducción del riesgo de mortalidad difiere según la clase de bifosfonato: estudio observacional de…
#Osteoporosis Int: la reducción del riesgo de mortalidad difiere según la clase de bifosfonato: estudio observacional de 15 años https://t.co/Bv6DppQhW9 https://t.co/0oiLcrelvJ
RT @iofbonehealth: #Osteoporosis Int: Mortality risk reduction differs according to #bisphosphonate class: a 15-year observational study ht…
In #osteoporosis, the Nitrogen BP #bisphosfonates (#alendronate and #risedronate) was associated with lower #mortalityrisks [pairwise HR, 0.66 (95% CI, 0.48–0.91)] #saludelamujer y #asistenciasanitaria frente a #vacacionesterapéuticas. https://t.co/sgGbYU
RT @iofbonehealth: #Osteoporosis Int: Mortality risk reduction differs according to #bisphosphonate class: a 15-year observational study ht…
RT @iofbonehealth: #Osteoporosis Int: Mortality risk reduction differs according to #bisphosphonate class: a 15-year observational study ht…
RT @iofbonehealth: #Osteoporosis Int: Mortality risk reduction differs according to #bisphosphonate class: a 15-year observational study ht…
#Osteoporosis Int: Mortality risk reduction differs according to #bisphosphonate class: a 15-year observational study https://t.co/ecGFNxefOY https://t.co/hQJFcLvIta
RT @Osteoporosis_NL: Nitrogen but not non-nitrogen bisphosphonates appear to be associated with better survival: a 15-year observational st…
@FractureLink @OsteoUHN @OsteoporosisCA @funnelll @GERAScentre
Nitrogen but not non-nitrogen bisphosphonates appear to be associated with better survival: a 15-year observational study. Bliuc D et al. Osteoporos Int. 2019 Jan 3 https://t.co/CzzjEdrJVI https://t.co/8G43uxF8gQ